A cost-effectiveness analysis of endoscopic eradication therapy for management of dysplasia arising in patients with Barrett’s oesophagus in the United Kingdom

References

• Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63(1):7–42.
   PubMed Web of Science ®Google Scholar
• Johansson J, Hakansson HO, Mellblom L, et al. Prevalence of precancerous and other metaplasia in the distal oesophagus and gastro-oesophageal junction. Scand J Gastroenterol. 2005;40(8):893–902.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Epithelial radiofrequency ablation for Barrett’s oesophagus. Interventional procedures guidance [IPG344]. London: NICE; 2010.
   Google Scholar
• National Institute for Health and Care Excellence. Barrett’s oesophagus: ablative therapy. Clinical guideline [CG106]. London: NICE; 2010.
   Google Scholar
• Gatenby P, Caygill C, Wall C, et al. Lifetime risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. World J Gastroenterol. 2014;20(28):9611–9617.
   PubMed Web of Science ®Google Scholar
• Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103(13):1049–1057.
   PubMedGoogle Scholar
• Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365(15):1375–1383.
   PubMed Web of Science ®Google Scholar
• Weusten B, Bisschops R, Coron E, et al. Endoscopic management of Barrett’s esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy. 2017;49(2):191–198.
   PubMed Web of Science ®Google Scholar
• Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111(1):30–50; quiz 51.
   PubMed Web of Science ®Google Scholar
• Cancer Research UK [cited 2018 Jan]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/oesophageal-cancer?_ga=2.109495173.1262586708.1517233566-932884114.1509353695.
   Google Scholar
• Curvers WL, Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105(7):1523–1530.
   PubMed Web of Science ®Google Scholar
• de Jonge PJ, van Blankenstein M, Looman CW, et al. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut. 2010;59(8):1030–1036.
   PubMed Web of Science ®Google Scholar
• Duits LC, Phoa KN, Curvers WL, et al. Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut. 2015;64(5):700–706.
   PubMed Web of Science ®Google Scholar
• Sharma P. Clinical practice. Barrett’s esophagus. N Engl J Med. 2009;361(26):2548–2556.
   PubMed Web of Science ®Google Scholar
• Inadomi JM, Somsouk M, Madanick RD, et al. A cost–utility analysis of ablative therapy for Barrett’s esophagus. Gastroenterology. 2009;136(7):2101–2114 e1–6.
   PubMed Web of Science ®Google Scholar
• Rastogi A, Puli S, El-Serag HB, et al. Incidence of esophageal adenocarcinoma in patients with Barrett’s esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008;67(3):394–398.
   PubMed Web of Science ®Google Scholar
• di Pietro M, Fitzgerald RC. Revised British Society of Gastroenterology recommendation on the diagnosis and management of Barrett's oesophagus with low-grade dysplasia. Gut. 2017;67(2):392–93.
   PubMed Web of Science ®Google Scholar
• Phoa KN, Pouw RE, Bisschops R, et al. Multimodality endoscopic eradication for neoplastic Barrett oesophagus: results of an European multicentre study (EURO-II). Gut. 2016;65(4):555–562.
   PubMed Web of Science ®Google Scholar
• Haidry RJ, Dunn JM, Butt MA, et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett’s esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology. 2013;145(1):87–95.
   PubMed Web of Science ®Google Scholar
• Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360(22):2277–2288.
   PubMed Web of Science ®Google Scholar
• Leggett CL, Gorospe EC, Wang KK. Endoscopic therapy for Barrett’s esophagus and early esophageal adenocarcinoma. Gastroenterol Clin North Am. 2013;42(1):175–185.
   PubMed Web of Science ®Google Scholar
• Phoa KN, Rosmolen WD, Weusten B, et al. The cost-effectiveness of radiofrequency ablation for Barrett’s esophagus with low-grade dysplasia: results from a randomized controlled trial (SURF trial). Gastrointest Endosc. 2017;86(1):120–129 e2.
   PubMed Web of Science ®Google Scholar
• Varagunam MB, Brand C, Cromwell D, et al. National Oesophago-Gastric Cancer Audit. NHS; 2017. Available from: https://www.nogca.org.uk/content/uploads/2017/12/NOGCA-Annual-Report-2017.pdf
   Google Scholar
• National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. London: 2014. Available from: https://www.nice.org.uk/media/default/about/what-we-do/our-programmes/developing-nice-guidelines-the-manual.pdf
   Google Scholar
• Hur C, Choi SE, Rubenstein JH, et al. The cost effectiveness of radiofrequency ablation for Barrett’s esophagus. Gastroenterology. 2012;143(3):567–575.
   PubMed Web of Science ®Google Scholar
• National Health Service. NHS Choices. Heartburn and gastro-oesophageal reflux disease – complications. 2016 [cited 2017 Nov 20]. Available from: https://www.nhs.uk/conditions/heartburn-and-acid-reflux/#complications-of-gord.
   Google Scholar
• Desai M, Saligram S, Gupta N, et al. Efficacy and safety outcomes of multimodal endoscopic eradication therapy in Barrett’s esophagus-related neoplasia: a systematic review and pooled analysis. Gastrointest Endosc. 2017;85(3):482–495 e4.
   PubMed Web of Science ®Google Scholar
• Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett’s esophagus with dysplasia. Gastroenterology. 2011;141(2):460–468.
   PubMed Web of Science ®Google Scholar
• Small AJ, Araujo JL, Leggett CL, et al. Radiofrequency ablation is associated with decreased neoplastic progression in patients with Barrett’s esophagus and confirmed low-grade dysplasia. Gastroenterology. 2015;149(3):567–576 e3; quiz e13–14.
   PubMed Web of Science ®Google Scholar
• Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311(12):1209–1217.
   PubMed Web of Science ®Google Scholar
• Das A, Wells C, Kim HJ, et al. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett’s esophagus. Endoscopy. 2009;41(5):400–408.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Clinical Guideline 106. Appendix 6: cost effectiveness analysis for Barrett’s oesophagus. London: 2010. Available from: https://www.nice.org.uk/guidance/cg106/evidence/ablative-therapy-full-guideline-appendix-6-health-economics-pdf-134747683
   Google Scholar
• Department of Health. NHS Reference cost 2015–2016. London: 2016. Available from: https://www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016
   Google Scholar
• Joint Formulary Committee. British National Formulary [cited 2017 Oct 4]. Available from: https://www.bnf.org/.
   Google Scholar
• Kind PH, Hardman G, Macran S. UK population norms for EQ-5D. York: Centre for Health Economics UoY; 1999. Available from: https://EconPapers.repec.org/RePEc:chy:respap:172chedp
   Google Scholar
• Office of National Statistics. National Life Tables, United Kingdom: 2012–2014. 2015. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/bulletins/nationallifetablesunitedkingdom/2015-09-23
   Google Scholar
• Office of National Statistics. UK Population estimates. 2017. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates#timeseries
   Google Scholar
• Masclee GC, Wilde P, Kuipers M, et al. The incidence of Barrett’s oesophagus and oesophageal adenocarcinoma in the United Kingdom and the Netherlands is levelling off. Aliment Pharmacol Ther. 2014;39(11):1321–1330.
   PubMed Web of Science ®Google Scholar
• Filby A, Taylor M, Lipman G, et al. Cost-effectiveness analysis of endoscopic eradication therapy for treatment of high-grade dysplasia in Barrett’s esophagus. J Comp Eff Res. 2017;6(5):425–436.
   PubMed Web of Science ®Google Scholar
• Esteban J, Gonzalez P, Gornals JB, et al. Cost-effectiveness of endoscopic treatment with radiofrequency ablation for patients with Barrett’s esophagus and high or low grade dysplasia in Spain. Value Health. 2016;19(7):A512–A513.
   PubMed Web of Science ®Google Scholar
• Soriano TT, Eslick GD, Vanniasinkam T. Long-term nutritional outcome and health related quality of life of patients following esophageal cancer surgery: a meta-analysis. Nutr Cancer. 2018;70(2):192–203.
   PubMed Web of Science ®Google Scholar
• Kauppila JH, Xie S, Johar A, et al. Meta-analysis of health-related quality of life after minimally invasive versus open oesophagectomy for oesophageal cancer. Br J Surg. 2017;104(9):1131–1140.
   PubMed Web of Science ®Google Scholar
• Fujii-Lau LL, Cinnor B, Shaheen N, et al. Recurrence of intestinal metaplasia and early neoplasia after endoscopic eradication therapy for Barrett’s esophagus: a systematic review and meta-analysis. Endosc Int Open. 2017;5(6):E430–E449.
   PubMed Web of Science ®Google Scholar
• Wani S, Rubenstein JH, Vieth M, Bergman J. Diagnosis and management of low-grade dysplasia in Barrett’s esophagus: expert review from the Clinical Practice Updates Committee of the American Gastroenterological Association. Gastroenterology. 2016;151(5):822–835.
   PubMed Web of Science ®Google Scholar
• Garside R, Pitt M, Somerville M, et al. Surveillance of Barrett’s oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol Assess. 2006;10(8):1–142, iii–iv.
   PubMed Web of Science ®Google Scholar
• Boger PC, Turner D, Roderick P, Patel P. A UK-based cost–utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barrett’s oesophagus. Aliment Pharmacol Ther. 2010;32(11–12):1332–1342.
   PubMed Web of Science ®Google Scholar